TREATMENT PATTERNS OF ADVANCED EGFR-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) IN LATIN AMERICA

被引：0
|
作者：
Alves, J. S. [1 ]
Watanabe de Oliveira, R. [1 ]
Oliveira, D. [2 ]
Medina, Y. [3 ]
Osorio, M. [4 ]
Tabares, M. [5 ]
Tamayo, C. [6 ]
Kano, B. [7 ]
Muller Bernz, I [7 ]
机构：
[1] Janssen Cilag Farmaceut Ltda, Sao Paulo, Brazil
[2] Johnson & Johnson Med Brazil, Sao Paulo, Brazil
[3] Johnson & Johnson, Janssen Pharmaceut Co, Bogota, Cun, Colombia
[4] IQVIA, Mexico City, DF, Mexico
[5] IQVIA, Buenos Aires, DF, Argentina
[6] IQVIA, Bogota, Cun, Colombia
[7] IQVIA, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
SA56
引用
收藏
页码：S552 / S552
页数：1
相关论文
共 50 条
  • [21] Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC)
    Gerald Schmid-Bindert
    Targeted Oncology, 2013, 8 : 15 - 26
  • [22] Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
    Paulina Bracht, Jillian Wilhelmina
    Karachaliou, Niki
    Berenguer, Jordi
    Pedraz-Valdunciel, Carlos
    Filipska, Martyna
    Codony-Servat, Carles
    Codony-Servat, Jordi
    Rosell, Rafael
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (12): : 2607 - 2614
  • [23] Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Tsiara, Anna
    Liontos, Michalis
    Kaparelou, Maria
    Zakopoulou, Roubini
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [24] Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis
    Zhang, Yaxiong
    Sheng, Jin
    Yang, Yunpeng
    Fang, Wenfeng
    Kang, Shiyang
    He, Yang
    Hong, Shaodong
    Zhan, Jianhua
    Zhao, Yuanyuan
    Xue, Cong
    Ma, Yuxiang
    Zhou, Ting
    Ma, Shuxiang
    Gao, Fangfang
    Qin, Tao
    Hu, Zhihuang
    Tian, Ying
    Hou, Xue
    Huang, Yan
    Zhou, Ningning
    Zhao, Hongyun
    Zhang, Li
    ONCOTARGET, 2016, 7 (15) : 20093 - 20108
  • [25] Third Line Therapy in EGFR Positive Advanced Non-Small Cell Lung Cancer
    Pande, Nikhil
    Joshi, Amit
    Noronha, Vanita
    Patil, Vijay
    Chougule, Anuradha
    Janu, Amit
    More, Sucheta
    Goud, Supriya
    Karpe, Ashay
    Ramaswamy, Anant
    Chandrasekharan, Arun
    Talreja, Vikas
    Goel, Alok
    Prabhash, Kumar
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1229 - S1230
  • [26] Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non–small cell lung cancer patients
    Xueyun Tan
    Sufei Wang
    Hui Xia
    Hebing Chen
    Juanjuan Xu
    Daquan Meng
    Zhihui Wang
    Yan Li
    Lian Yang
    Yang Jin
    Investigational New Drugs, 2023, 41 : 463 - 472
  • [27] FIRST-LINE TREATMENT EFFICACY IN EGFR-POSITIVE NON-SMALL CELL LUNG CANCER: A NETWORK META-ANALYSIS
    van Nimwegen, K.
    Nientker, K.
    Cakar, E.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
  • [28] Non-small Cell Lung Cancer (NSCLC) Necitumumab in advanced squamous NSCLC approved with EGFR-Expression
    Sankawa, Yuri
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (06) : 395 - 396
  • [29] Treatment of non-small cell lung cancer (NSCLC)
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Darwiche, Kaid
    Boutsikou, Efimia
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Karapantzos, Ilias
    Huang, Haidong
    Spyratos, Dionysios
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396
  • [30] Underlying Mechanisms That Potentially Affect Prognosis to EGFR-TKI in EGFR-Positive Patients with Non-Small Cell Lung Cancer
    Cheng, Y.
    Ma, L.
    Liu, Y.
    Xin, Y.
    Chen, Y.
    Zhu, J.
    Zhang, L.
    Yang, C.
    Wu, C.
    Zhang, T.
    Wang, S.
    Li, Z.
    Bai, L.
    Mao, X.
    Zhang, T.
    Lin, J.
    Shi, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S396 - S397
12345